Diagnosis and therapy of cancer (i.e. leukemia and prostate) tailored for the patient subgroup re-sistant to TRAIL induced apopt
TRAIL has recently emerged as a novel potential anticancer agent. However, cancer cells are in specific patients resistant to TRAIL induced apoptosis. Therefore the efficacy of chemotherapy for treatment of CLL, MCL, HNSCC, bladder or prostate carci-noma is often limited due to resistance to TRAIL induced apoptosis. The technology provides a method for identification of these non-responders. Moreover, a polynucleotide encoding the modified TRAIL can serve as drug against such cancer diseases of this specific patient subgroup.
Further Information: PDF
Deutsches Krebsforschungszentrum DKfZ
Phone: +49-6221-422958
Contact
Regina Otto
Media Contact
All latest news from the category: Technology Offerings
Newest articles
A universal framework for spatial biology
SpatialData is a freely accessible tool to unify and integrate data from different omics technologies accounting for spatial information, which can provide holistic insights into health and disease. Biological processes…
How complex biological processes arise
A $20 million grant from the U.S. National Science Foundation (NSF) will support the establishment and operation of the National Synthesis Center for Emergence in the Molecular and Cellular Sciences (NCEMS) at…
Airborne single-photon lidar system achieves high-resolution 3D imaging
Compact, low-power system opens doors for photon-efficient drone and satellite-based environmental monitoring and mapping. Researchers have developed a compact and lightweight single-photon airborne lidar system that can acquire high-resolution 3D…
